Daiichi Sankyo struggles despite olmesartan growth
This article was originally published in Scrip
Executive Summary
Despite continued strength for the angiotensin II antagonist olmesartan (Benicar/Olmetec), a stronger yen, divestment of non-core operations and a change in year end at the company's European subsidiary all took their toll on Daiichi Sankyoin the first quarter, when total net sales slipped by 13% to ¥203.7 billion ($1.88 billion).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.